Literature DB >> 3671246

The management of severe hypercalcaemia.

P Altmann1, J Cunningham.   

Abstract

Entities:  

Mesh：

Year:  1987        PMID： 3671246      PMCID： PMC2428226          DOI： 10.1136/pgmj.63.736.77

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  5 in total

1.  Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  F J van Breukelen; O L Bijvoet; A T van Oosterom
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

2.  Prostaglandins as mediators of hypercalcemia associated with certain types of cancer.

Authors:  H W Seyberth; G V Segre; J L Morgan; B J Sweetman; J T Potts; J A Oates
Journal:  N Engl J Med       Date:  1975-12-18       Impact factor: 91.245

3.  Pathogenesis of hypercalcemia in lymphosarcoma cell leukemia. Role of an osteoclast activating factor-like substance and a mechanism of action for glucocorticoid therapy.

Authors:  G R Mundy; M E Rick; R Turcotte; M A Kowalski
Journal:  Am J Med       Date:  1978-10       Impact factor: 4.965

4.  Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.

Authors:  D L Douglas; T Duckworth; R G Russell; J A Kanis; C J Preston; F E Preston; M A Prenton; J S Woodhead
Journal:  Lancet       Date:  1980-05-17       Impact factor: 79.321

5.  Intravenous etidronate in the management of malignant hypercalcemia.

Authors:  E Ryzen; R R Martodam; M Troxell; A Benson; A Paterson; K Shepard; R Hicks
Journal:  Arch Intern Med       Date:  1985-03
  5 in total
  1 in total

1.  Management of hyperparathyroid patients with grave hypercalcemia.

Authors:  L E Tisell; G Hedbäck; S Jansson; G Lindstedt; B F Zachrisson
Journal:  World J Surg       Date:  1991 Nov-Dec       Impact factor: 3.352
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.